Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
Cerveira N, Loureiro B, Bizarro S, Correia C, Torres L, Lisboa S, Vieira J, Santos R, Pereira D, Moreira C, Chacim S, Domingues N, Espírito-Santo A, Oliveira I, Moreira I, Viterbo L, Martins Â, Teixeira MR, Mariz JM.
Cerveira N, et al. Among authors: mariz jm.
BMC Cancer. 2018 Dec 12;18(1):1245. doi: 10.1186/s12885-018-5167-y.
BMC Cancer. 2018.
PMID: 30541488
Free PMC article.